Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Singleton

Showing results (301-310 of 304) with videos related to

Pageof 31
Sort By:
You have reached the last page of results.This site can display upto 304 results.
Cell Reports|December 7, 2017
Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary ConvergenceKatherine R Singleton, Lorin Crawford, Elizabeth Tsui, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
MCB-613 exploits a collateral sensitivity in drug resistant <i>EGFR</i>-mutant non-small cell lung cancer through covalent inhibition of KEAP1Christopher F Bassil, Gray R Anderson, Benjamin Mayro, et al.
Nature Communications|January 14, 2026
EGFR inhibitor-resistant lung cancers exhibit collateral sensitivity to a covalent, cysteine-independent KEAP1 oligomerizing molecular bridgeChristopher F Bassil, Kerry Dillon, Gray R Anderson, et al.
Journal of Clinical Medicine|November 19, 2020
Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical TrialMichael J Brownstein, Neal G Simon, Jeffrey D Long, et al.
Pageof 31

Showing results (301-310 of 304) with videos related to

Sort By:
Pageof 31
You have reached the last page of results.This site can display upto 304 results.
Cell Reports|December 7, 2017
Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary ConvergenceKatherine R Singleton, Lorin Crawford, Elizabeth Tsui, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
MCB-613 exploits a collateral sensitivity in drug resistant <i>EGFR</i>-mutant non-small cell lung cancer through covalent inhibition of KEAP1Christopher F Bassil, Gray R Anderson, Benjamin Mayro, et al.
Nature Communications|January 14, 2026
EGFR inhibitor-resistant lung cancers exhibit collateral sensitivity to a covalent, cysteine-independent KEAP1 oligomerizing molecular bridgeChristopher F Bassil, Kerry Dillon, Gray R Anderson, et al.
Journal of Clinical Medicine|November 19, 2020
Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical TrialMichael J Brownstein, Neal G Simon, Jeffrey D Long, et al.
Pageof 31